The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Protagonist Therapeutics Inc shares valued at $784,715 were sold by MOLINA ARTURO MD on Jan 20 ’26. At $82.48 per share, MOLINA ARTURO MD sold 9,514 shares. The insider’s holdings dropped to 97,266 shares worth approximately $8.25 million following the completion of this transaction.
Also, PATEL DINESH V PH D sold 34,438 shares, netting a total of over 2,840,446 in proceeds. Following the sale of shares at $82.48 each, the insider now holds 580,505 shares.
Before that, Ali Asif had sold 8,588 shares from its account. In a trade valued at $708,338, the Chief Financial Officer traded Protagonist Therapeutics Inc shares for $82.48 each. Upon closing the transaction, the insider’s holdings decreased to 8,588 shares, worth approximately $6.62 million.
As published in their initiating research note from Barclays on September 17, 2025, Protagonist Therapeutics Inc [PTGX] has been an Overweight and the price target has been revised to $72. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid September. As of June 17, 2025, Citigroup has initiated its “Buy” rating for PTGX. Earlier on December 06, 2024, Goldman initiated its rating. Their recommendation was “a Neutral” for PTGX stock.
Analyzing PTGX Stock Performance
On last trading session, Protagonist Therapeutics Inc [NASDAQ: PTGX] rose 1.07% to $84.79. The stock’s lowest price that day was $80.65, but it reached a high of $85.2 in the same session. During the last five days, there has been a drop of approximately -0.52%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 122.55%.
Is Protagonist Therapeutics Inc subject to short interest?
Stocks of Protagonist Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 1.41 million shares to 7.29 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 5.88 million shares. A jump of 19.32% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.75 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.75.
Which companies own the most shares of Protagonist Therapeutics Inc (PTGX)?
In terms of Protagonist Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 110 in the next 12 months, up nearly 31.12% from the previous closing price of $83.89. Analysts anticipate Protagonist Therapeutics Inc stock to reach 112 by 2026, with the lowest price target being 108. In spite of this, 4 analysts ranked Protagonist Therapeutics Inc stock as Buy at the end of 2026. On December 06, 2024, BMO Capital Markets assigned a price target of “an Outperform” to the stock and initiated coverage with a $62.
